MEDIVATION INC's ticker is MDVN and the CUSIP is 58501N101. A total of 340 filers reported holding MEDIVATION INC in Q4 2014. The put-call ratio across all filers is 0.83 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2016 | $124,486,000 | +87.4% | 2,064,463 | +42.9% | 0.05% | +70.4% |
| Q1 2016 | $66,422,000 | -28.2% | 1,444,581 | -24.5% | 0.03% | -27.0% |
| Q4 2015 | $92,546,000 | +5.5% | 1,914,505 | -7.2% | 0.04% | 0.0% |
| Q3 2015 | $87,699,000 | -45.0% | 2,063,503 | +47.9% | 0.04% | -41.3% |
| Q2 2015 | $159,313,000 | -39.0% | 1,395,035 | -31.0% | 0.06% | -37.6% |
| Q1 2015 | $261,130,000 | +77.9% | 2,023,174 | +37.3% | 0.10% | +77.2% |
| Q4 2014 | $146,760,000 | -11.2% | 1,473,329 | -11.8% | 0.06% | -13.6% |
| Q3 2014 | $165,188,000 | +22.7% | 1,670,768 | -4.3% | 0.07% | +24.5% |
| Q2 2014 | $134,592,000 | +40.3% | 1,746,147 | +17.2% | 0.05% | +35.9% |
| Q1 2014 | $95,928,000 | -5.0% | 1,490,249 | -5.8% | 0.04% | -2.5% |
| Q4 2013 | $100,934,000 | +21.2% | 1,581,544 | +13.9% | 0.04% | +11.1% |
| Q3 2013 | $83,254,000 | +26.4% | 1,388,955 | +3.7% | 0.04% | +16.1% |
| Q2 2013 | $65,884,000 | – | 1,339,088 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Knoll Capital Management, LLC | 2,484,101 | $158,535,000 | 79.84% |
| Cormorant Asset Management, LP | 546,900 | $34,903,000 | 10.13% |
| BB BIOTECH AG | 1,479,706 | $94,435,000 | 5.04% |
| PFM Health Sciences, LP | 2,719,859 | $173,581,000 | 3.49% |
| Partner Investment Management, L.P. | 219,981 | $14,039,000 | 3.19% |
| Orbimed Advisors | 3,123,500 | $199,342,000 | 2.93% |
| Antipodean Advisors LLC | 525,000 | $33,506,000 | 2.90% |
| Eventide Asset Management | 134,800 | $8,603,000 | 2.65% |
| Bain Capital Public Equity Management, LLC | 1,428,117 | $91,142,000 | 2.58% |
| BENNETT LAWRENCE MANAGEMENT L L C/NY | 257,055 | $16,405,000 | 2.52% |